Larimar Therapeutics, Inc. (LRMR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.830.00%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · LRMR
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||||||
| Revenues | — | — | — | — | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Total Revenues | — | — | — | — | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating Expenses & Income | |||||||||||||
| R&D Expenses | 157.3 | 154.2 | 73.3 | 27.7 | 24.3 | 38.4 | 31.4 | 20.8 | 47.9 | 40.8 | 39.9 | 54.6 | 27.4 |
| Operating Income | (179.0) | (172.5) | (90.9) | (41.8) | (36.5) | (50.5) | (42.8) | (23.2) | (61.1) | (53.0) | (58.2) | (73.8) | (35.5) |
| Earnings from Continuing Operations | |||||||||||||
| Interest Expense | — | — | — | — | — | — | — | 1.8 | 1.9 | 0.2 | 0.5 | 0.8 | 0.9 |
| Interest & Investment Income | — | — | — | — | — | — | — | 2.0 | — | — | — | — | — |
| Net Interest Expenses | — | — | — | — | — | — | — | (0.2) | — | — | — | — | — |
| Other Non-Operating Income / Expenses | 6.4 | 6.8 | 10.3 | 4.8 | 1.2 | (0.2) | 0.3 | 0.1 | (0.2) | 1.0 | 0.3 | (0.5) | (0.9) |
| Asset Writedown | — | — | — | 0.0 | 0.0 | 0.0 | — | 0.1 | — | — | — | — | — |
| EBT, Incl. Unusual Items | — | (165.7) | (80.6) | (36.9) | (35.4) | (50.6) | (42.5) | (23.2) | (61.4) | (52.0) | (57.9) | (74.3) | (36.5) |
| Income Tax Expense | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Income | |||||||||||||
| Net Income | (172.6) | (165.7) | (80.6) | (36.9) | (35.4) | (50.6) | (42.5) | (23.1) | (61.4) | (52.0) | (57.9) | (74.3) | (36.5) |
| Per Share | |||||||||||||
| Basic EPS | — | — | (1.32) | (0.84) | (1.37) | (2.95) | (3.57) | — | — | — | — | — | — |
| Diluted EPS | — | — | (1.32) | (0.84) | (1.37) | (2.95) | (3.57) | — | — | — | — | — | — |
| Basic Weighted Avg Shares | — | — | 61.3 | 43.9 | 25.8 | 17.2 | 11.9 | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | — | — | 61.3 | 43.9 | 25.8 | 17.2 | 11.9 | — | — | — | — | — | — |
| Supplemental | |||||||||||||
| EBIT | (179.0) | (172.5) | (90.9) | (41.8) | (36.5) | (50.5) | (42.8) | (23.2) | (61.1) | (53.0) | (58.2) | (73.8) | (35.5) |
| Effective Tax Rate | — | — | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.